• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Earnings Beat Require Action From Biogen Stock Investors?

    Simply Wall St·10/28/2026 19:24:45
    Listen to the news
    • Biogen reported third quarter 2026 revenue of US$2.80b compared with US$2.53b a year earlier, alongside an adjusted profit of US$2.62 per share that exceeded analyst estimates and a slight increase to full year adjusted EPS guidance.
    • The earnings release showed Biogen's growth portfolio, including recently acquired Apellis products, contributing materially to revenue, while reported GAAP results still reflected a small quarterly loss and lower year to date net income than the prior year.
    • We will now look at how Biogen's raised full year adjusted EPS guidance influences the existing investment narrative built around its growth portfolio.

    Scan how Biogen's earnings story compares with other healthcare stocks that are leaning on newer therapies and acquisitions by checking out the hand picked 34 healthcare AI stocks that are reshaping treatment pipelines.

    Biogen Investment Narrative Recap

    To own Biogen, you need to be comfortable with a simple idea. The older multiple sclerosis portfolio is under pressure, while the newer neurology and immunology therapies plus Apellis assets carry more of the load. The Q3 2026 beat and slightly higher adjusted EPS guidance support that growth portfolio story, but they sit against a GAAP quarterly loss and thinner margins.

    The key near term swing factor is execution on recent launches like LEQEMBI, SKYCLARYS and ZURZUVAE, alongside the Apellis products. The biggest risk is that erosion in the legacy multiple sclerosis drugs and higher R&D and deal related costs outpace uptake of these newer treatments. This quarter’s numbers do not remove that risk.

    The Q3 2026 report, with US$2.80b in revenue and adjusted EPS of US$2.62, ties directly into that setup. Management slightly raised full year adjusted EPS guidance to US$12.60 at the midpoint. That puts more attention on whether Biogen can keep expanding its growth portfolio while controlling expenses under the Fit for Growth program.

    Investors weighing catalysts might link this to the earlier update that Biogen’s multi product growth portfolio has already overtaken multiple sclerosis revenue. The earnings beat and guidance tweak keep focus on operational execution in Alzheimer’s, nephrology and other newer areas, while the main watch points remain competitive pressure in multiple sclerosis and the impact of one off items on reported profitability.

    What The New Earnings Guidance Assumes For Biogen

    Biogen's narrative projects US$11.0b revenue and US$2.2b earnings by 2029. That profile aligns with current analyst assumptions of 3.3% yearly revenue growth and an increase in earnings of about US$1.4b from US$834.6m today.

    Uncover why Biogen's fair value indicates a 3% potential downside to its current price, which leaves little room for error.

    NasdaqGS:BIIB 1-Year Stock Price Chart
    NasdaqGS:BIIB 1-Year Stock Price Chart

    Exploring Other Perspectives

    You also need to weigh a tougher pricing story. The most cautious analysts were assuming roughly flat sales through 2029, with revenue around US$10.3b and earnings near US$1.7b, before this Biogen report. That view reflects more reimbursement pushback on high cost drugs. These new numbers may shift that debate, so explore both narratives.

    Explore 4 other Biogen fair value estimates, including one that suggests as much as 26% downside from the current price.

    Decide For Yourself

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Biogen?

    Once you have a view on Biogen, it can help to compare it with other opportunities that match your risk tolerance and income or growth goals. The Simply Wall St Screener can surface different types of stocks so you can build a broader watchlist that fits how you like to invest.

    • If you want potential mispriced opportunities with solid foundations, start with a carefully filtered 29 high quality undervalued stocks that pair strong fundamentals with more modest expectations baked into current prices.
    • For investors who care most about balance sheet strength and financial resilience, focus on companies in the list of solid balance sheet and fundamentals (24 results) to see which ones might better handle tough operating conditions.
    • If you are hunting for lesser known ideas rather than widely covered large caps, spend time with the 21 high quality undiscovered gems that highlight under the radar businesses with strong underlying metrics.